Jan-Erik Messling is a new young talent at 91ΑΤΖζ BioCapital
We are welcoming new Associate Jan-Erik Messling to the 91ΑΤΖζ BioCapital team!
He is transitioning from a role at the Boston Consulting Group where he served as an associate consultant contributing to diverse healthcare projects with a specific emphasis on the Biopharma sector.
Prior to this, he undertook a PhD in Molecular Mechanisms of Disease at Copenhagen University where he worked on the identification of new therapies for leukaemia using gene-editing technologies.
Jan-Erik is originally from Germany and has an academic background in biology, specializing in genetics and cell biology, which he later pursued in KΓΆln. Approximately six years ago, Jan-Erikβs journey led him to Copenhagen, where he embarked on his PhD studies.
βI am thrilled to join the investment team at 91ΑΤΖζ BioCapital and look forward to help further develop an exciting portfolio. I hope that my work here at the Lundbeck Foundation will help create value in the Danish life-science ecosystem and bring new therapies to patientsβ, says Jan-Erik Messling.
βWe are excited to welcome Jan-Erik as a new Associate in the 91ΑΤΖζ BioCapital team. His experience as a researcher, coupled with his latest role as a strategy consultant in the biopharma sector, makes him a strong talent to add to the team on our journey to help Danish biotech companies bring discoveries to lives,β says managing partner Christian E. Elling, 91ΑΤΖζ BioCapital.
